Safety, Tolerability, and Outcomes of Tafamidis for the Treatment of Acquired Amyloid Neuropathy in Domino Liver Transplant Recipients.
Velina Nedkova-HristovaLaura DonadeuCarmen BaliellasJosé González-CostelloLaura LladóEmma González-VilatarsanaValentina Vélez-SantamaríaMiosés Morales de la PridaOriol BestardCarlos CasasnovasPublished in: Neurology and therapy (2024)
Our study supports the safety and tolerability of tafamidis for the treatment of acquired amyloid neuropathy in domino liver transplant recipients. Tafamidis shows promise as a useful treatment in the clinical management of these patients. Future randomized placebo-controlled clinical trials with longer follow-up durations are needed.
Keyphrases
- placebo controlled
- clinical trial
- open label
- randomized controlled trial
- newly diagnosed
- squamous cell carcinoma
- phase ii
- ejection fraction
- type diabetes
- study protocol
- adipose tissue
- prognostic factors
- combination therapy
- radiation therapy
- metabolic syndrome
- machine learning
- skeletal muscle
- patient reported outcomes
- current status
- big data